Literature DB >> 7033836

Possible mixed agonist--antagonist activity of D-sulpiride at dopamine receptor level in man.

F Benfenati, P Bernardi, P Cortelli, M Capelli, C Adani, L Calzà, L F Agnati.   

Abstract

The effects of different doses of D-sulpiride (1, 6, 12 and 25 mg, i.v.) on arterial blood pressure (ABP), heart rate (HR) and prolactin (PRL), growth hormone (GH), insulin and gastrin secretions have been studied in 8 normal men. D-Sulpiride increased systolic ABP with a maximum effect rather 12 mg i.v., while it had only slight effects on diastolic ABP and HR. PRL secretion was increased by D-sulpiride in a dose-dependent way, while insulin secretion was lowered and GH secretion slightly enhanced only in a restricted range of doses (6 mg and 12 mg i.v., respectively). Gastrin secretion seemed to be unaffected by D-sulpiride at any of the tested doses. These results are discussed in view of a possible mixed agonist--antagonist activity of D-sulpiride at dopamine receptor level in contrast with the relatively pure antagonistic action of the levo isomer.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7033836     DOI: 10.1016/0304-3940(81)90147-6

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  3 in total

1.  3[H]-Sulpiride labels mesolimbic non-dopaminergic sites that bind antidepressant drugs.

Authors:  J G Csernansky; C A Csernansky; L E Hollister
Journal:  Experientia       Date:  1985-11-15

2.  Effect of sulpiride isomers on gastric acid and gastrin secretion in healthy man.

Authors:  R Caldara; E Masci; M Cambielli; A Tittobello; V Piepoli; C Barbieri
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Dopamine and pain sensitivity: neither sulpiride nor acute phenylalanine and tyrosine depletion have effects on thermal pain sensations in healthy volunteers.

Authors:  Susanne Becker; Marta Ceko; Mytsumi Louis-Foster; Nathaniel M Elfassy; Marco Leyton; Yoram Shir; Petra Schweinhardt
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.